Susquehanna International Group, LLP Albireo Pharma, Inc. Transaction History

Susquehanna International Group, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $428,089 - $691,711	26,231 Added 254.82%	36,525 $707,000
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $254,405 - $511,693	-13,722 Reduced 57.14%	10,294 $204,000
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $517,870 - $729,863	-21,632 Reduced 47.39%	24,016 $716,000
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $438,082 - $646,889	-20,674 Reduced 31.17%	45,648 $1.06 Million
Q3 2021 Nov 15, 2021	SELL	$27.36 - $35.98 $716,175 - $941,812	-26,176 Reduced 28.3%	66,322 $2.07 Million
Q2 2021 Aug 11, 2021	BUY	$28.9 - $36.87 $1.17 Million - $1.5 Million	40,571 Added 78.13%	92,498 $3.25 Million
Q1 2021 May 17, 2021	BUY	$32.03 - $42.85 $515,811 - $690,056	16,104 Added 44.95%	51,927 $1.83 Million
Q4 2020 Feb 16, 2021	BUY	$31.56 - $42.16 $560,221 - $748,382	17,751 Added 98.22%	35,823 $1.34 Million
Q3 2020 Nov 16, 2020	SELL	$23.19 - $41.61 $149,459 - $268,176	-6,445 Reduced 26.29%	18,072 $603,000
Q2 2020 Aug 14, 2020	BUY	$14.82 - $29.92 $363,341 - $733,548	24,517 New	24,517 $649,000
Q2 2018 Aug 14, 2018	SELL	$28.9 - $37.31 $907,893 - $1.17 Million	-31,415 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$26.78 - $39.35 $841,293 - $1.24 Million	31,415 New	31,415 $1.02 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.